Insider and Congress filings

Eli Lilly and Company (LLY)

Drug Manufacturers, listed on NYSE.

S&P 500429 insider transactions197 Congress tradeslast filed Nov 4, 2026

Download on the App StoreGet it on Google Play

Free on iOS and Android

EarningsQ3 FY2026 · reported Oct 29, 2026

Eli Lilly beat by 31.0% on adjusted EPS.

$7.48 a share against a $5.71 consensus. Revenue $24.4B against $22.6B, a beat of 8.0%.

EPS

Reported$7.48
Consensus$5.71

Revenue

Reported$24.4B
Consensus$22.6B

Beat 6

Next report Feb 3, 2027. Consensus $11.20 a share.

Every quarter

Money managers13F filings for Jun 30, 2026

10

of the 97 fund managers GetSignal tracks list Eli Lilly among their largest positions. Cliff Asness held the most, $1.2B.

Tracked managers’ Q2 2026 moves

Castle Hookopened+$558.0M
Adagetrimmed−$276.6M
ARK Investadded+$77.5M

Each manager’s 13F against the one before, priced at the Jun 30, 2026 close: an estimate, from each manager’s 15 largest moves. Not investment advice.

Every manager

Insider tradesForm 4 · 6 open-market filings shown

Six open-market sales, 5 of them under 10b5‑1 plans.

May 6, 2026Nov 2, 2026

SalesSales under a plan

5 of 6 under a plan

A median 1 business day from trade to filing. Form 4 is due within two.

Every filing
Companyfrom the company's filings and listing, as of Nov 8, 2026

About Eli Lilly and Company

Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
David A. Ricks
Employees
50,000
Listed since
-
Market value
$1.3T
Price to earnings (12 mo)
43.8
Net income per share, as reported (12 mo)
$30.92
Dividend yield
0.49%

www.lilly.com

GetSignal News2 articles · newest first

GetSignal News

HeadlineSourceDate
Eli Lilly says it now expects 2026 revenue of $85 billion to $87 billionEli Lilly said its 2026 non-GAAP earnings per share range is $35.50 to $36.50, down from $35.50 to $37.00, and excludes acquired IPR&D incurred after June 30, 2026.Form 8-KAug 5, 2026
Eli Lilly shareholders elect four directors at May 4 annual meetingProposals to eliminate the classified board and supermajority voting did not reach the 80% vote required.Form 8-KMay 7, 2026

Written by GetSignal with AI from SEC filings and the company's own press releases; each article links to its source. Not investment advice.

Company news from every company we cover

Earnings6 reported quarters · next on Feb 3, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Oct 29, 2026$7.48$5.71$24.4B$22.6BEPS beatRevenue beat
Q2 FY2026reported Aug 5, 2026$8.38$6.40$23.0B$20.8BEPS beatRevenue beat
Q1 FY2026reported Apr 30, 2026$8.55$6.97$19.8B$17.8BEPS beatRevenue beat
Q4 FY2025reported Feb 4, 2026$7.54$6.91$19.3B$17.9BEPS beatRevenue beat
Q3 FY2025reported Oct 30, 2025$7.02$5.69$17.6B$16.1BEPS beatRevenue beat
Q2 FY2025reported Aug 7, 2025$6.31$5.60$15.6B$14.7BEPS beatRevenue beat

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on LLY, newest first
FirmRatingTargetActionDate
Cantor FitzgeraldOverweight$1,600Raised from $1,440
Freedom BrokerNot stated$1,600Target set
ArgusBuy$1,550Target set
UBSBuy$1,625Raised from $1,425
BMO CapitalOutperform$1,650Raised from $1,400
BofA SecuritiesBuy$1,497Target set
Wells FargoOverweight$1,500Raised from $1,330
Truist SecuritiesBuy$1,612Raised from $1,376
BernsteinOutperform$1,450Raised from $1,385
LeerinkOutperform$1,316Target set
Goldman SachsBuy$1,413Target set
Morgan StanleyOverweight$1,430Raised from $1,419
GuggenheimBuy$1,284Raised from $1,273
BerenbergBuy$1,400Target set
HSBCReduce$940Target set
RBC CapitalOutperform$1,500Raised from $1,250
JefferiesBuy$1,350Target set
Wolfe ResearchNot stated$1,350Target set
BarclaysOverweight$1,400Raised from $1,350
Deutsche BankBuy$1,285Target set
ScotiabankSector Outperformrated Oct 30, 2026$1,300Target set
DaiwaBuy$1,230Target set

Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice. A rating with its own date under it is the firm's latest from the past 120 days, where the note stated none.

4 other firms rated LLY in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 9, 2026.

Proxy statementas filed for fiscal 2025 · proxy filed Mar 20, 2026

Executive pay

David A. Ricks’s pay as CEO came to $36.7M for fiscal 2025.
ExecutiveSalaryStock awardsOtherTotal
David A. RicksChair, President, and Chief Executive Officer$1.7M$23.3M$11.7M$36.7M
Daniel M. SkovronskyM.D., Ph.D. Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs$1.5M$12.0M$4.3M$17.8M
Anat HakimExecutive Vice President, General Counsel and Secretary$1.0M$6.0M$2.8M$9.8M
Lucas MontarceExecutive Vice President and Chief Financial Officer$1.0M$5.0M$2.5M$8.5M
Jake Van NaardenExecutive Vice President and President, Lilly Oncology and Head of Corporate Business Development$920K$4.5M$2.2M$7.6M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing

13F filings13F positions as of Jun 30, 2026

Institutional holders

4,643 institutions reported Eli Lilly shares in 13F filings for Jun 30, 2026.
HolderValueSharesShares vs prior qtr% of shares out
Lilly Endowment Inc$108.4B90,376,978-1.7%10.13%
BlackRock, Inc.$81.0B67,540,400+1.7%7.57%
Vanguard Capital Management LLC$64.2B53,528,868+0.3%6.00%
PNC Financial Services Group, Inc.$61.6B51,322,7200.0%5.75%
State Street Corp$43.4B36,215,754+1.7%4.05%
FMR LLC$34.1B28,462,475+8.1%3.19%
Capital Research Global Investors$25.0B20,873,140-15.3%2.34%
Vanguard Portfolio Management LLC$25.0B20,859,217-0.6%2.34%
Geode Capital Management, LLC$24.3B20,310,858+0.6%2.28%
Morgan Stanley$19.5B16,226,398+5.1%1.82%
Capital World Investors$19.1B15,902,642+1.8%1.78%
T. Rowe Price Associates, Inc.$16.7B13,911,839-0.6%1.56%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

13F filings10 managers

Tracked fund managers holding LLY

ManagerValueSharesShare of book
Cliff AsnessAQR Capital Management$1.2B1,035,6050.4%
Adage Capital Partners$871.0M726,1991.2%
Castle Hook Partners$558.0M465,1872.6%
OrbiMed$309.3M257,9005.8%
Woodline Partners$293.7M244,8610.9%
Trexquant Investment$109.0M90,8500.6%
Ray DalioBridgewater Associates$104.4M87,0230.4%
Cathie WoodARK Invest$92.7M77,2540.6%
Glenview CapitalLarry Robbins$69.3M57,7711.3%
Samlyn Capital$44.5M37,1250.7%

10 of the 97 fund managers we track list LLY shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.

Form 46 filings shown · newest filing first

Open-market insider trades

InsiderActionSharesPriceValueTrade dateDelay
(business days)
Anat HakimEVP, GC & SecretarySold · scheduled5,000$1402.52$7.0MNov 2, 2026filed Nov 3, 20261d
Patrik JonssonEVP & President, LLY Int'lSold · scheduled6,500$1175.10$7.6MAug 17, 2026filed Aug 18, 20261d
Donald A. ZakrowskiSVP, Finance, & CAOSold · scheduled2,000$1185.01$2.4MAug 10, 2026filed Aug 11, 20261d
Anat HakimEVP, GC & SecretarySold · scheduled5,000$1190.00$6.0MAug 7, 2026filed Aug 10, 20261d
Ilya YuffaEVP&Pres, LLY USA&Global CapabSold · scheduled2,500$1150.77$2.9MJun 10, 2026filed Jun 11, 20261d
Lilly Endowment IncSold · 2 lines15,828$995.36$15.8MMay 6, 2026filed May 7, 20261d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
David A. RicksPresident, Chair, and CEOGift23,538Nov 3, 2026
Adrienne S. BrownEVP, President LLY ImmTax withholding1,099Nov 1, 2026
Adrienne S. BrownEVP, President LLY ImmOption exercise2,530Nov 1, 2026
Kenneth L. CusterEVP & President, Card Met HlthTax withholding1,425Nov 1, 2026
Kenneth L. CusterEVP & President, Card Met HlthOption exercise3,220Nov 1, 2026
Eric DozierEVP, Chief People OfficerTax withholding1,019Nov 1, 2026
Eric DozierEVP, Chief People OfficerOption exercise2,300Nov 1, 2026
Edgardo HernandezEVP & Pres., Mfg. OperationsTax withholding1,123Nov 1, 2026
Edgardo HernandezEVP & Pres., Mfg. OperationsOption exercise2,530Nov 1, 2026
Lucas MontarceEVP & CFOTax withholding678Nov 1, 2026
Lucas MontarceEVP & CFOOption exercise1,610Nov 1, 2026
Daniel SkovronskyEVP, CS&PO & Pres. LRLGift119Nov 2, 2026
Gabrielle SulzbergerDirectorStock award3.998Oct 19, 2026
Ralph AlvarezDirectorStock award10Oct 19, 2026
J. Erik FyrwaldDirectorStock award7.995Oct 19, 2026
Juan R. LucianoDirectorStock award13Oct 19, 2026
Gabrielle SulzbergerDirectorStock award4.257Sep 21, 2026
J. Erik FyrwaldDirectorStock award8.513Sep 21, 2026
Juan R. LucianoDirectorStock award14Sep 21, 2026
Ralph AlvarezDirectorStock award11Sep 21, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

STOCK Act20 disclosures of 197 on record · median 27d of the 45 allowed

Congress trades in LLY

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Michael A. RulliFiled lateStockSale$1,001 - $15,000+29.4% since the saleEstimated exit price $1,046.12, close on Tue Dec 2, 2025Current price $1,354.00, close on Fri Nov 6Dec 2, 2025Aug 7, 2026248d
Michael A. RulliFiled lateStockPurchase$1,001 - $15,000+25.3% since the tradeEstimated entry price $1,080.36, close on Fri Jan 2Current price $1,354.00, close on Fri Nov 6Jan 2, 2026Aug 7, 2026217d
Michael A. RulliStockSale$1,001 - $15,000+13.6% since the saleEstimated exit price $1,191.74, close on Wed Jul 1Current price $1,354.00, close on Fri Nov 6Jul 1, 2026Aug 7, 202637d
Alan ArmstrongSelfStockSale (Full)$1,001 - $15,000+54.2% since the saleEstimated exit price $878.24, close on Fri Mar 27Current price $1,354.00, close on Fri Nov 6Mar 27, 2026Jul 21, 2026116d
Dan NewhouseSpouseStockSale$1,001 - $15,000+13.9% since the saleEstimated exit price $1,188.58, close on Fri Jul 10Current price $1,354.00, close on Fri Nov 6Jul 10, 2026Jul 17, 20267d
Ro KhannaStockPurchase$1,001 - $15,000+27.2% since the tradeEstimated entry price $1,064.15, close on Tue Jun 2Current price $1,354.00, close on Fri Nov 6Jun 2, 2026Jul 6, 202634d
Gilbert Ray Cisneros, Jr.StockPurchase$50,001 - $100,000+19.2% since the tradeEstimated entry price $1,136.37, close on Wed Jun 10Current price $1,354.00, close on Fri Nov 6Jun 10, 2026Jul 2, 202622d
Ro KhannaStockSale$1,001 - $15,000+40.6% since the saleEstimated exit price $963.33, close on Fri May 1Current price $1,354.00, close on Fri Nov 6May 1, 2026Jun 9, 202639d
Byron DonaldsStockPurchase$1,001 - $15,000+44.7% since the tradeEstimated entry price $935.58, close on Thu Apr 2Current price $1,354.00, close on Fri Nov 6Apr 2, 2026May 13, 202641d
Ro KhannaStockSale$1,001 - $15,000+45.7% since the saleEstimated exit price $929.55, close on Mon Apr 13Current price $1,354.00, close on Fri Nov 6Apr 13, 2026May 11, 202628d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000+46.8% since the tradeEstimated entry price $922.50, close on Tue Apr 14Current price $1,354.00, close on Fri Nov 6Apr 14, 2026May 8, 202624d
Lizzie FletcherStockSale$1,001 - $15,000+42.0% since the saleEstimated exit price $953.30, close on Wed Apr 8Current price $1,354.00, close on Fri Nov 6Apr 8, 2026May 1, 202623d
Gilbert Ray Cisneros, Jr.StockSale$1,001 - $15,000+37.5% since the saleEstimated exit price $985.08, close on Fri Mar 13Current price $1,354.00, close on Fri Nov 6Mar 13, 2026Apr 7, 202625d
Angus S. King Jr.SpouseStockSale (Full)$1,001 - $15,000+30.2% since the saleEstimated exit price $1,040.00, close on Fri Feb 13Current price $1,354.00, close on Fri Nov 6Feb 13, 2026Mar 24, 202639d
David TaylorStockPurchase$1,001 - $15,000+32.5% since the tradeEstimated entry price $1,022.02, close on Thu Feb 26Current price $1,354.00, close on Fri Nov 6Feb 26, 2026Mar 6, 20268d
David TaylorStockSale$1,001 - $15,000+29.6% since the saleEstimated exit price $1,044.67, close on Mon Feb 9Current price $1,354.00, close on Fri Nov 6Feb 9, 2026Feb 20, 202611d
Ro KhannaStockPurchase$1,001 - $15,000+27.2% since the tradeEstimated entry price $1,064.29, close on Fri Jan 23Current price $1,354.00, close on Fri Nov 6Jan 23, 2026Feb 6, 202614d
David TaylorStockSale$1,001 - $15,000+30.4% since the saleEstimated exit price $1,038.40, close on Fri Jan 16Current price $1,354.00, close on Fri Nov 6Jan 16, 2026Feb 2, 202617d
Angus S. King Jr.SpouseStockPurchase$1,001 - $15,000+25.4% since the tradeEstimated entry price $1,079.45, close on Mon Dec 29, 2025Current price $1,354.00, close on Fri Nov 6Dec 29, 2025Jan 26, 202628d
Markwayne MullinJointStockPurchase$15,001 - $50,000+25.4% since the tradeEstimated entry price $1,079.45, close on Mon Dec 29, 2025Current price $1,354.00, close on Fri Nov 6Dec 29, 2025Jan 16, 202618d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in LLY filterable by party, chamber, type and account.

STOCK Act15 members · estimate, as of Nov 8, 2026

Members of Congress reporting a position

15 members report a position of $1,000 or more (estimated).
MemberParty, chamberEstimated positionShare of their portfolio
J. French HillRepublican · House$500,001 - $1,000,0005.5%
Robert BresnahanRepublican · House$100,001 - $250,0001.6%
Sheldon WhitehouseDemocrat · Senate$100,001 - $250,0000.8%
Gilbert Ray Cisneros, Jr.Democrat · House$100,001 - $250,0000.5%
Josh GottheimerDemocrat · House$50,001 - $100,0000.3%
Julie JohnsonDemocrat · House$50,001 - $100,0000.7%
Steve CohenDemocrat · House$50,001 - $100,0002.4%
Jared MoskowitzDemocrat · House$50,001 - $100,0001.3%
Lucy McBathDemocrat · House$50,001 - $100,0001.0%
David TaylorRepublican · House$15,001 - $50,0001.6%
Byron DonaldsRepublican · House$15,001 - $50,0005.4%
John BoozmanRepublican · Senate$15,001 - $50,0000.8%
Ron WydenDemocrat · Senate$15,001 - $50,0000.2%
Shelley Moore CapitoRepublican · Senate$1,001 - $15,0000.5%
Tony WiedRepublican · House$1,001 - $15,0000.1%

A further 2 members report positions estimated under $1,000; they are not listed.

The largest estimated position is in the $500,001 - $1,000,000 band. Estimate, as of Nov 8, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 9, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on LLY show and how current they are.

Are insiders buying or selling LLY?

Across the 6 most recent open-market filings shown here, 0 were purchases and 6 were sales. 5 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded LLY?

Michael A. Rulli, Alan Armstrong, Dan Newhouse, Ro Khanna, Gilbert Ray Cisneros, Jr., Byron Donalds and others disclosed LLY transactions in the filings shown here.

Which members of Congress hold LLY?

15 members of Congress report a position of $1,000 or more in LLY in the estimate we hold as of Nov 8, 2026. The largest estimated position belongs to J. French Hill; the next largest, in the $100,001 - $250,000 band, include Robert Bresnahan and Sheldon Whitehouse. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

Is LLY in the S&P 500 or the Nasdaq 100?

Eli Lilly and Company is a current member of the S&P 500, per the membership list we hold as of Nov 8, 2026. Current members of either index get a page here whatever their filing history.

How quickly are LLY trades disclosed?

Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 27 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track